NO781035L - T fremgangsmaate til fremstilling av et farmasoeytisk prepara - Google Patents
T fremgangsmaate til fremstilling av et farmasoeytisk preparaInfo
- Publication number
- NO781035L NO781035L NO781035A NO781035A NO781035L NO 781035 L NO781035 L NO 781035L NO 781035 A NO781035 A NO 781035A NO 781035 A NO781035 A NO 781035A NO 781035 L NO781035 L NO 781035L
- Authority
- NO
- Norway
- Prior art keywords
- extract
- glucanase
- physarum
- fysarum
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- 239000000284 extract Substances 0.000 claims description 49
- 241000224485 Physarum Species 0.000 claims description 33
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical group O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 17
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 16
- 229960003942 amphotericin b Drugs 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 229940121375 antifungal agent Drugs 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000000843 anti-fungal effect Effects 0.000 claims description 8
- 239000003429 antifungal agent Substances 0.000 claims description 8
- 229960000988 nystatin Drugs 0.000 claims description 8
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 8
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000012286 Chitinases Human genes 0.000 claims description 4
- 108010022172 Chitinases Proteins 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108010055851 Acetylglucosaminidase Proteins 0.000 claims description 3
- 102100036495 Di-N-acetylchitobiase Human genes 0.000 claims description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004413 flucytosine Drugs 0.000 claims description 2
- 230000001878 mycolytic effect Effects 0.000 claims 3
- 229940088598 enzyme Drugs 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 108010014251 Muramidase Proteins 0.000 description 8
- 102000016943 Muramidase Human genes 0.000 description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 235000010335 lysozyme Nutrition 0.000 description 7
- 241000222511 Coprinus Species 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 229940051921 muramidase Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241001225321 Aspergillus fumigatus Species 0.000 description 3
- 208000036641 Aspergillus infections Diseases 0.000 description 3
- 241000224486 Physarum polycephalum Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000002909 Aspergillosis Diseases 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000222065 Lycoperdon Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001302210 Sida <water flea> Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 206010067409 Trichophytosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229940049735 fusarium extract Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01025—Beta-mannosidase (3.2.1.25), i.e. mannanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01039—Glucan endo-1,3-beta-D-glucosidase (3.2.1.39)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01052—Beta-N-acetylhexosaminidase (3.2.1.52)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01058—Glucan 1,3-beta-glucosidase (3.2.1.58)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01073—Licheninase (3.2.1.73)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01075—Glucan endo-1,6-beta-glucosidase (3.2.1.75)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01084—Glucan 1,3-alpha-glucosidase (3.2.1.84), i.e. mutanase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB12919/77A GB1576891A (en) | 1977-03-28 | 1977-03-28 | Antimicrobial compositions containing extracts of light enzymes from physarum species |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO781035L true NO781035L (no) | 1978-09-29 |
Family
ID=10013545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO781035A NO781035L (no) | 1977-03-28 | 1978-03-22 | T fremgangsmaate til fremstilling av et farmasoeytisk prepara |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS542310A (fr) |
| AT (1) | AT363589B (fr) |
| AU (1) | AU519066B2 (fr) |
| BE (1) | BE865369A (fr) |
| CA (1) | CA1107646A (fr) |
| DE (1) | DE2813282A1 (fr) |
| DK (1) | DK134678A (fr) |
| ES (1) | ES468236A1 (fr) |
| FI (1) | FI780933A (fr) |
| FR (1) | FR2385730A1 (fr) |
| GB (1) | GB1576891A (fr) |
| GR (1) | GR71706B (fr) |
| IE (1) | IE46698B1 (fr) |
| IL (1) | IL54364A0 (fr) |
| NL (1) | NL7803291A (fr) |
| NO (1) | NO781035L (fr) |
| NZ (1) | NZ186783A (fr) |
| PT (1) | PT67826B (fr) |
| SE (1) | SE7803456L (fr) |
| ZA (1) | ZA781758B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58134014A (ja) * | 1982-02-03 | 1983-08-10 | Rooto Seiyaku Kk | 義歯洗浄用組成物 |
| US4542020A (en) * | 1984-08-17 | 1985-09-17 | E. R. Squibb & Sons, Inc. | Long-lasting adhesive antifungal suppositories |
| JPH0261164A (ja) * | 1988-08-27 | 1990-03-01 | Hisaka Works Ltd | 処理槽への内槽装填・取り出し方法およびそれに用いる移載車。 |
| JPH0261163A (ja) * | 1988-08-27 | 1990-03-01 | Hisaka Works Ltd | 繊維材料取り出し方法およびそれに用いる装置 |
| AU3257397A (en) * | 1996-06-07 | 1998-01-07 | Gist-Brocades B.V. | Antifungal compositions |
-
1977
- 1977-03-28 GB GB12919/77A patent/GB1576891A/en not_active Expired
-
1978
- 1978-03-22 NO NO781035A patent/NO781035L/no unknown
- 1978-03-23 NZ NZ186783A patent/NZ186783A/xx unknown
- 1978-03-23 AU AU34479/78A patent/AU519066B2/en not_active Expired
- 1978-03-27 JP JP3526978A patent/JPS542310A/ja active Pending
- 1978-03-27 IL IL54364A patent/IL54364A0/xx unknown
- 1978-03-27 PT PT67826A patent/PT67826B/pt unknown
- 1978-03-27 GR GR55801A patent/GR71706B/el unknown
- 1978-03-27 ES ES468236A patent/ES468236A1/es not_active Expired
- 1978-03-28 FR FR7808962A patent/FR2385730A1/fr active Granted
- 1978-03-28 BE BE186314A patent/BE865369A/fr unknown
- 1978-03-28 ZA ZA00781758A patent/ZA781758B/xx unknown
- 1978-03-28 SE SE7803456A patent/SE7803456L/xx unknown
- 1978-03-28 AT AT0215978A patent/AT363589B/de not_active IP Right Cessation
- 1978-03-28 FI FI780933A patent/FI780933A/fi not_active Application Discontinuation
- 1978-03-28 DE DE19782813282 patent/DE2813282A1/de not_active Withdrawn
- 1978-03-28 NL NL7803291A patent/NL7803291A/xx not_active Application Discontinuation
- 1978-03-28 CA CA299,788A patent/CA1107646A/fr not_active Expired
- 1978-03-28 DK DK134678A patent/DK134678A/da not_active Application Discontinuation
- 1978-03-29 IE IE623/78A patent/IE46698B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE46698B1 (en) | 1983-08-24 |
| AT363589B (de) | 1981-08-10 |
| IL54364A0 (en) | 1978-06-15 |
| PT67826A (en) | 1978-04-01 |
| SE7803456L (sv) | 1978-09-29 |
| AU3447978A (en) | 1979-09-27 |
| CA1107646A (fr) | 1981-08-25 |
| PT67826B (en) | 1979-09-27 |
| DK134678A (da) | 1978-09-29 |
| FI780933A (fi) | 1978-09-29 |
| ATA215978A (de) | 1981-01-15 |
| FR2385730A1 (fr) | 1978-10-27 |
| GB1576891A (en) | 1980-10-15 |
| FR2385730B1 (fr) | 1981-07-10 |
| ZA781758B (en) | 1979-05-30 |
| NL7803291A (nl) | 1978-10-02 |
| GR71706B (fr) | 1983-06-21 |
| BE865369A (fr) | 1978-09-28 |
| NZ186783A (en) | 1980-12-19 |
| ES468236A1 (es) | 1978-12-01 |
| IE780623L (en) | 1978-09-28 |
| DE2813282A1 (de) | 1978-10-12 |
| JPS542310A (en) | 1979-01-09 |
| AU519066B2 (en) | 1981-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| San-Blas et al. | Host-parasite relationships in the yeastlike form of Paracoccidioides brasiliensis strain IVIC Pb9 | |
| EP0295956B1 (fr) | Utilisation d'un polysaccharide lié a une protéine pour préparer un médicament destiné au traitement du SIDA. | |
| US4062941A (en) | Method for treating fungal infections using cell lytic enzymes | |
| Ashby | Macrophomina phaseoli (Maubl.) comb. nov., the pycnidial stage of Rhizoctonia bataticola (Taub.) Butl | |
| Kobayashi et al. | Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum | |
| Kim et al. | Production of soluble β-glucan from the cell wall of Saccharomyces cerevisiae | |
| US4985543A (en) | Lectins and antiretroviral drugs containing the lectins as active ingredient | |
| Hehre et al. | Dextran-splitting anaerobic bacteria from the human intestine | |
| Hirst | The effect of a polysaccharide-splitting enzyme on streptococcal infection | |
| KR0149477B1 (ko) | Hiv 활성의 저해제 | |
| US2797183A (en) | Nystatin and method of producing it | |
| US5891861A (en) | Composition and method for treating fungal disease in animals | |
| NO781035L (no) | T fremgangsmaate til fremstilling av et farmasoeytisk prepara | |
| US4144327A (en) | Antimicrobial composition comprising lytic enzymes from physarum and an antimycotic agent | |
| US4328313A (en) | Method of producing a plaque dispersing enzyme | |
| EP0201332A2 (fr) | Composé ayant une activité contre les infections | |
| JPH0662426B2 (ja) | 腫瘍の血管新生を抑制するための治療薬 | |
| DE2048848A1 (de) | Verfahren zur Herstellung eines Korn plexes aus RNS und Polysacchand, Verfahren zur Gewinnung der Polysacchand Komponente und ihre Verwendung zur Herstellung von Arzneimitteln | |
| EP0295961A2 (fr) | Polysaccharides et médicaments anti-viraux les contenant comme principe actif | |
| Faergemann et al. | Antimycotic activity of propane-1, 2-diol (propylene glycol) | |
| Watanabe et al. | Cytotoxicity of pyocin S2 to tumor and normal cells and its interaction with cell surfaces | |
| Cooper | Phialophora verrucosa and other chromoblastomycotic fungi | |
| Shepard | Growth and development of T strain pleuropneumonialike organisms in human epidermoid carcinoma cells (HeLa) | |
| Sulkin et al. | Effect of zymosan on bacteriophage clearance | |
| US6015796A (en) | Method for treating AIDS |